Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Nuclear Medicine

• Publication date

  2018-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2967/jnumed.118.209841PMID 29653971PMCID PMC6225536
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gastroenteropancreatic Neuroendocrine Tumours

  2019cited by this paper
• Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy

  2018cited by this paper
• Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors

  2018cited by this paper
• Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.

  2018cited by this paper
• Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

  2017cited by this paper
• Radionuclide Therapy for Neuroendocrine Tumors

  2017cited by this paper
• Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy

  2017cited by this paper
• Microsurgery guided by sequential preoperative lymphography using 68Ga-NEB PET and MRI in patients with lower-limb lymphedema

  2017cited by this paper
• Novel “Add-On” Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents

  2017cited by this paper
• Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography

  2017cited by this paper
• 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice

  2017cited by this paper
• The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis

  2017cited by this paper
• Transformative Nanomedicine of an Amphiphilic Camptothecin Prodrug for Long Circulation and High Tumor Uptake in Cancer Therapy.

  2017cited by this paper
• Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.

  2016cited by this paper
• Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

  2016cited by this paper
• Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume

  2016cited by this paper
• Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.

  2016cited by this paper
• Somatostatin Analog Therapy in Small Cell Lung Cancer.

  2016cited by this paper
• Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB

  2015cited by this paper
• Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

  2015cited by this paper
• Prospective Study of 68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients

  2015cited by this paper
• In vivo albumin labeling and lymphatic imaging

  2014cited by this paper
• Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.

  2014cited by this paper
• In Vivo Labeling of Serum Albumin for PET

  2014cited by this paper
• A review of the use of somatostatin analogs in oncology

  2013cited by this paper
• DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177Lu-Radionuclide Tumor Therapy in Mice

  2013cited by this paper
• Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men

  2013cited by this paper
• The expanding role of somatostatin analogs in the management of neuroendocrine tumors.

  2012cited by this paper
• Impact of albumin on drug delivery--new applications on the horizon.

  2012cited by this paper
• Current Concepts on Gastric Carcinoid Tumors

  2012cited by this paper
• EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting

  2010cited by this paper
• Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

  2009cited by this paper
• Gastroenteropancreatic neuroendocrine tumours.

  2008cited by this paper
• Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

  2008cited by this paper
• Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney

  2007cited by this paper
• Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.

  2004cited by this paper
• Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney.

  2001influential reference
• Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta.

  1993influential reference

• Developments of radioligands with an albumin-binding moiety of 4-(P-Iodophenyl) butyric acid.

  2025cites this paper
• Tailored Reaction Conditions and Automated Radiolabeling of [177Lu]Lu-PSMA-ALB-56 in a 68Ga Setting: The Critical Impact of Antioxidant Concentrations

  2025cites this paper
• Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics

  2025cites this paper
• Probes with Tailored Pharmacokinetics for Radiotheranostics.

  2025cites this paper
• Recent Trends in Radiopharmaceuticals: Focused on Drug Delivery to the Targeted Tissues.

  2025cites this paper
• Albumin Binding as a Strategy for Improving Tumor Targeting of Radiolabeled Compounds.

  2025cites this paper
• Radiopharmaceuticals: from discovery to theranostics

  2025cites this paper
• Deciphering the Tumor Uptake of Heterobivalent (SST2/Albumin) [64Cu]Cu-NODAGA-cLAB-TATEs

  2025cites this paper
• Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands

  2024cites this paper
• The heterobivalent (SSTR2/albumin) radioligand [67Cu]Cu-NODAGA-cLAB4-TATE enables efficient somatostatin receptor radionuclide theranostics

  2024cites this paper
• Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma

  2024influential citation
• FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model.

  2024cites this paper
• Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study

  2024cites this paper
• Radiopharmaceuticals for Cancer Diagnosis and Therapy

  2024cites this paper
• Landscape of Nuclear Medicine in China and Its Progress on Theranostics.

  2024cites this paper
• Current Status and Perspectives of Novel Radiopharmaceuticals with Heterologous Dual-targeted Functions: 2013-2023.

  2024cites this paper
• Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2–Positive Neuroendocrine Tumors

  2024cites this paper
• Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors

  2024cites this paper
• Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin αvβ3-positive tumors: A first-in-human study

  2024cites this paper
• Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE With and Without Amino Acid Infusion

  2023cites this paper
• Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade

  2023cites this paper
• Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

  2023cites this paper
• Dosimetric analysis of a compartmental model for radioligand uptake in tumor lesions

  2023cites this paper
• Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects

  2023cites this paper
• Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics

  2023cites this paper
• Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals

  2022cites this paper
• A Comparison of Evans Blue and 4-(p-Iodophenyl)butyryl Albumin Binding Moieties on an Integrin αvβ6 Binding Peptide

  2022cites this paper
• 86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis.

  2022cites this paper
• Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic

  2022cites this paper
• Determinants of target absorbed dose in radionuclide therapy.

  2022cites this paper
• A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

  2022cites this paper
• Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence

  2022cites this paper
• Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225

  2022cites this paper
• Imaging-Guided Targeted Radionuclide Tumor Therapy: From Concept to Clinical Translation.

  2022cites this paper
• New biology of pheochromocytoma and paraganglioma.

  2022cites this paper
• Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors

  2022cites this paper
• Role of Somatostatin Signalling in Neuroendocrine Tumours

  2022cites this paper
• Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

  2022cites this paper
• Deciphering albumin-directed drug delivery by imaging.

  2022cites this paper
• Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy

  2021cites this paper
• Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

  2021cites this paper
• Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy

  2021cites this paper
• Radiopharmaceuticals: An insight into the latest advances in medical uses and regulatory perspectives

  2021cites this paper
• Albutate-1, a Novel Long-Circulating Radiotracer Targeting the Somatostatin Receptor Subtype 2

  2021cites this paper
• Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China.

  2021cites this paper
• Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors

  2021cites this paper
• PSMA Theranostics: Science and Practice

  2021cites this paper
• Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy

  2021cites this paper
• Radioreceptor Therapy

  2021cites this paper
• "Clickable" Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals.

  2021cites this paper
• Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

  2021cites this paper
• New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders

  2020cites this paper
• Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC

  2020cites this paper
• Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE

  2020cites this paper
• Strategies for Improving Stability and Pharmacokinetic Characteristics of Radiolabeled Peptides for Imaging and Therapy.

  2020cites this paper
• Peptide Targeting Methods

  2020cites this paper
• Acetylcholine Imaging in Psychosis

  2020cites this paper
• 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

  2020cites this paper
• Radioligand Development for PET Imaging of the Vesicular Acetylcholine Transporter (VAChT) in the Brain

  2020cites this paper
• Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response

  2019cites this paper
• Mini-review: Targeted radiopharmaceuticals incorporating reversible, low molecular weight albumin binders.

  2019cites this paper
• Radioiodinated Portable Albumin Binder as a Versatile Agent for in Vivo Imaging with Single-Photon Emission Computed Tomography.

  2019cites this paper
• Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies.

  2019cites this paper
• Reply: Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks

  2019cites this paper
• Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors

  2019cites this paper
• Molecular imaging and radionuclide therapy of paraganglioma and pheochromocytoma.

  2019cites this paper
• A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed

  2019cites this paper
• 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

  2019cites this paper
• A look ahead: future directions of SSR-directed imaging and therapy in meningioma

  2019cites this paper
• Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future

  2019cites this paper
• An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides.

  2019cites this paper
• Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study

  2018cites this paper
• Reply: Different Radionuclides in DOTA-EB-TATE Effect Different Uptake in Somatostatin Receptor–Positive HEK293 Cells

  2018cites this paper
• New Developments in Peptide Receptor Radionuclide Therapy

  2018cites this paper
• The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?

  2018cites this paper
• Somatostatin receptor PET ligands - the next generation for clinical practice.

  2018cites this paper
• Different Radionuclides in DOTA-EB-TATE Effect Different Uptake in Somatostatin Receptor–Positive HEK293 Cells

  2018cites this paper
• Clinical Issues Related to Fluid Management during 177Lu-Peptide Receptor Radionuclide Therapy in Metastatic Neuroendocrine Tumors with Carcinoid Heart Disease

  2018cites this paper
• Clinical value of 99mTc-HYNIC-TOC SPECT/CT for the diagnosis primary small cell neuroendocrine carcinomas of the nasal cavity and paranasal sinuses.

  2018cites this paper
• Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE.

  2018cites this paper
• Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

  2018cites this paper
• Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent.

  2018cites this paper
• Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG.

  2018cites this paper